Carregant...
Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells
Immunotherapy approaches currently make their way into the clinics to improve the outcome of standard radiochemotherapy (RCT). The programed cell death receptor ligand 1 (PD-L1) is one possible target that, upon blockade, allows T cell-dependent antitumor immune responses to be executed. To date, it...
Guardat en:
| Publicat a: | Front Immunol |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5177615/ https://ncbi.nlm.nih.gov/pubmed/28066420 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2016.00610 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|